Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitrofurantoin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Adalvo
Deal Size : Undisclosed
Deal Type : Partnership
CNX and Adalvo Sign Deal for Nitrofurantoin PR Commercialization
Details : Through the partnership, Nitrofurantoin PR-Generic (nitrofurantoin), will be available in the UK as the first generic version. It is indicated for the treatment of acute uncomplicated UTIs.
Product Name : Nitrofurantoin PR-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
December 16, 2024
Lead Product(s) : Nitrofurantoin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Adalvo
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
